Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (DE:NOV)
XETRA:NOV
Holding DE:NOV?
Track your performance easily
See the Price Targets and Ratings of:
NOV Analyst Ratings
Moderate Buy
9 Buy
5 Hold
2 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NOV Stock 12 Month Forecast
Average Price Target
€126.43
▲(23.32% Upside)
| Highest Price Target€147.47 | Average Price Target€126.43 | Lowest Price Target€75.07 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Deutsche Bank
Reiterated
10/31/24
J.P. Morgan
Reiterated
10/30/24
Erste Group
Downgraded
10/28/24
DZ BANK AG
Reiterated
10/22/24
Bernstein
Reiterated
10/21/24
Kepler Capital
Reiterated
10/15/24
Bank of America Securities
Reiterated
10/02/24
Barclays
Reiterated
09/30/24
Citi
Reiterated
09/27/24
Berenberg Bank
€130.71
Hold
27.50%
Upside
Reiterated
09/26/24
Berenberg Reiterates Hold Rating on Novo Nordisk (NOVOB:DC) (NVO)Berenberg analyst Kerry Holford reiterated a Hold rating and DKK975.00 price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO).
Goldman Sachs
€143.44
Buy
39.92%
Upside
Reiterated
09/23/24
Novo Nordisk (0QIU) Receives a Buy from Goldman Sachs
Jefferies
€77.08
Sell
-24.81%
Downside
Reiterated
09/20/24
Novo CB1 drug weight loss at 'lower-end of hopes,' says JefferiesNovo CB1 drug weight loss at 'lower-end of hopes,' says Jefferies
Guggenheim
€132.99→€135.8
Buy
32.46%
Upside
Reiterated
08/19/24
Novo Nordisk price target raised to DKK 1,013 from DKK 992 at GuggenheimNovo Nordisk price target raised to DKK 1,013 from DKK 992 at Guggenheim
Stifel Nicolaus
€129.37→€128.03
Buy
24.88%
Upside
Reiterated
08/09/24
Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK955 at StifelStifel analyst Eric Le Berrigaud lowered the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK955.00 (from DKK965.00) while maintaining a Buy rating.
Best Analysts Covering Novo Nordisk
Which Analyst Should I Follow If I Want to Buy DE:NOV and Sell After:
1 Month
xxx
Success Rate
32/50 ratings generated profit
Average Return
+2.28%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.00% of your transactions generating a profit, with an average return of +2.28% per trade.
3 Months
xxx
Success Rate
36/50 ratings generated profit
Average Return
+7.47%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 72.00% of your transactions generating a profit, with an average return of +7.47% per trade.
1 Year
Success Rate
25/30 ratings generated profit
Average Return
+33.96%
reiterated a buy rating last month
Copying Emily Field's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +33.96% per trade.
2 Years
xxx
Success Rate
41/50 ratings generated profit
Average Return
+44.05%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 82.00% of your transactions generating a profit, with an average return of +44.05% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NOV Analyst Recommendation Trends
Rating
Jun 24
Jul 24
Aug 24
Sep 24
Oct 24
Strong Buy
0
0
0
0
0
Buy
21
28
25
26
23
Hold
9
10
7
12
15
Sell
2
3
4
4
4
Strong Sell
0
0
0
0
0
total
32
41
36
42
42
Each month's total comprises the sum of three months' worth of ratings.
NOV Financial Forecast
NOV Stock Forecast FAQ
What is DE:NOV’s average 12-month price target, according to analysts?
Based on analyst ratings, Novo Nordisk’s 12-month average price target is €126.43.
What is DE:NOV’s upside potential, based on the analysts’ average price target?
Novo Nordisk has 23.32% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Novo Nordisk a Buy, Sell or Hold?
Novo Nordisk has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 5 hold ratings and 2 sell ratings.
What is Novo Nordisk’s share price target?
The average share price target for Novo Nordisk is €126.43. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €147.47 ,and the lowest forecast is €75.07. The average share price target represents 23.32% Increase from the current price of €102.52.
The highest analyst share price target is €147.47 ,and the lowest forecast is €75.07. The average share price target represents 23.32% Increase from the current price of €102.52.
What do analysts say about Novo Nordisk?
Novo Nordisk’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.
How can I buy shares of Novo Nordisk?
To buy shares of DE:NOV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.